Not finding it? Sign in to also search OpenAlex live.
-
An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial
Jun‐ichi Nishimura, Antoine Soubret, Simon Buatois, Jean‐Eric Charoin, Sasha Sreckovic, Christoph Marcus Bucher, +21 more
3citations -
COMPOSER Part 4: An Optimized Dosing Strategy for Crovalimab in the Treatment of Complement Inhibitor-Naïve or -Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria
Régis Peffault de Latour, Simona Sica, Julia G. Ramos, Jules Hernández‐Sánchez, Jin Seok Kim, Anna Kiialainen, +11 more
3citations -
Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria2024 American Journal of Hematology article Immunology and Microbiology Complement system in diseases Open access
Phillip Scheinberg, Diego V. Clé, Jin Seok Kim, Erfan Nur, Mustafa Nuri Yenerel, Wilma Barcellini, +15 more
52citations -
Pharmacokinetic characterization and exposure–response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria2025 British Journal of Clinical Pharmacology article Immunology and Microbiology Complement system in diseases Open access
Valérie F. Cosson, Rong Fu, Austin Gladston Kulasekararaj, Jun‐ichi Nishimura, Jens Panse, Alexander Röth, +14 more
10citations -
Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies2025 Annals of Hematology article Immunology and Microbiology Complement system in diseases Open access
Jens Panse, Bing Han, Jaroslav Čermák, Fernando Ataúlfo González Fernández, Akihiko Gotoh, Austin Gladston Kulasekararaj, +10 more
1citations -
Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long‐term results from the phase I/II COMPOSER trial2023 European Journal Of Haematology article Immunology and Microbiology Complement system in diseases Open access
Alexander Röth, Satoshi Ichikawa, Yoshikazu Ito, Jin Seok Kim, Zsolt Nagy, Naoshi Obara, +13 more
20citations -
Patient-Reported Outcomes (PROs) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Crovalimab and Eculizumab: Results from the Phase III Randomized COMMODORE 2 and COMMODORE 1 Trials
Jens Panse, Jaroslav Čermák, Olena Kyselova, Akihiko Gotoh, Fahri Şahin, Hubert Schrezenmeier, +3 more
4citations -
S183: PHASE III RANDOMIZED, MULTICENTER, OPEN-LABEL COMMODORE 1 TRIAL: COMPARISON OF CROVALIMAB VS ECULIZUMAB IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
Phillip Scheinberg, Diego V. Clé, Valentina Giai, Marek Hus, Jin Seok Kim, Cristina Barrenetxea Lekue, +11 more
5citations -
Phase III Randomized COMMODORE 1 Trial: 2-Year Safety and Efficacy of Crovalimab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Switched from Eculizumab2024 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Phillip Scheinberg, Diego V. Clé, Bérangère Devalet, Valentina Giai, Cristina Barrenetxea Lekue, Hsuan‐Yu Lin, +12 more
0citations -
Essai de phase III randomisé, multicentrique et en ouvert COMMODORE 1 : comparaison du crovalimab et de l’éculizumab chez des patients atteints d’hémoglobinurie paroxystique nocturne (HPN) déjà traités par un inhibiteur du complément
C. Tessier, L. Terriou, Phillip Scheinberg, Diego V. Clé, Valentina Giai, M. Hus, +10 more
0citations -
Mitigating Drug–Target–Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors2023 Clinical Pharmacology & Therapeutics article Immunology and Microbiology Complement system in diseases Open access
Jun‐ichi Nishimura, Antoine Soubret, Noriko Arase, Simon Buatois, Masaki Hotta, Jean‐Eric Charoin, +23 more
10citations -
Real-World Adherence with Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria Compared with Previously Reported Oral Medication Adherence Rates2024 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
David Dingli, Brian Patrick Mulherin, Peter Hillmen, Barbara Czech, Jens Panse
1citations -
Switching between complement inhibitors in patients with PNH: A real-world analysis of strategy, efficacy, and safety.2025 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Morag Griffin, Bruno Fattizzo, Jong Wook Lee, Richard J. Kelly, Roochi Trikha, Yasutaka Ueda, +10 more
0citations
18 results